Clearside Biomedical (CLSD) News Today $1.01 -0.02 (-1.46%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$0.99 -0.02 (-2.46%) As of 08:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 MeetingMarch 24 at 7:05 AM | globenewswire.comClearside Biomedical announces presentations on CLS-AXMarch 21, 2025 | markets.businessinsider.comClearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease SummitMarch 20, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Downgraded to "Sell" Rating by StockNews.comStockNews.com cut Clearside Biomedical from a "hold" rating to a "sell" rating in a research note on Tuesday.March 19, 2025 | marketbeat.comShort Interest in Clearside Biomedical, Inc. (NASDAQ:CLSD) Expands By 34.3%Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) was the target of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 767,400 shares, a growth of 34.3% from the February 13th total of 571,300 shares. Based on an average trading volume of 258,500 shares, the days-to-cover ratio is presently 3.0 days. Approximately 1.1% of the shares of the company are short sold.March 17, 2025 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Stock Crosses Below 50 Day Moving Average - What's Next?Clearside Biomedical (NASDAQ:CLSD) Stock Crosses Below Fifty Day Moving Average - What's Next?March 14, 2025 | marketbeat.comClearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025March 12, 2025 | globenewswire.comClearside Biomedical's (CLSD) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a report on Thursday.March 7, 2025 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a report on Thursday.March 7, 2025 | marketbeat.comClearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AXMarch 6, 2025 | markets.businessinsider.comClearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMDMarch 6, 2025 | globenewswire.comClearside Biomedical (CLSD) to Release Earnings on TuesdayClearside Biomedical (NASDAQ:CLSD) will be releasing earnings after the market closes on Tuesday, March 11, Financial Modeling Prep reports.March 4, 2025 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest UpdateClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) was the target of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 571,300 shares, a drop of 26.5% from the January 31st total of 777,800 shares. Based on an average daily trading volume, of 246,400 shares, the days-to-cover ratio is presently 2.3 days.March 3, 2025 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of "Buy" by BrokeragesShares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have been given an average rating of "Buy" by the six ratings firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-montMarch 2, 2025 | marketbeat.comInsider Buying: Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Acquires 15,000 Shares of StockClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) Director Clay Thorp bought 15,000 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were acquired at an average price of $0.92 per share, with a total value of $13,800.00. Following the acquisition, the director now owns 176,141 shares of the company's stock, valued at $162,049.72. This represents a 9.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.February 25, 2025 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Director Purchases $13,800.00 in StockFebruary 25, 2025 | insidertrades.comClearside Biomedical’s partner in China granted acceptance of arcatus NDAFebruary 21, 2025 | markets.businessinsider.comClearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular EdemaFebruary 20, 2025 | globenewswire.comClearside Biomedical's SWOT analysis: innovative eye treatment stock faces pivotal trialFebruary 18, 2025 | msn.comClearside Biomedical (NASDAQ:CLSD) Shares Cross Above 50 Day Moving Average - Should You Sell?Clearside Biomedical (NASDAQ:CLSD) Share Price Crosses Above 50-Day Moving Average - Should You Sell?February 15, 2025 | marketbeat.comJonesResearch sees buying opportunity in Clearside ahead of 2025 updatesFebruary 11, 2025 | markets.businessinsider.comClearside reports progress in wet AMD treatment trialsFebruary 10, 2025 | msn.comClearside announces additional data from CLS-AX ODYSSEY Phase 2b trialFebruary 10, 2025 | markets.businessinsider.comClearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 MeetingFebruary 10, 2025 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of "Buy" from BrokeragesClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) has been assigned an average rating of "Buy" from the six ratings firms that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price objFebruary 5, 2025 | marketbeat.comClearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual ConferenceFebruary 4, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Stock Passes Below 50-Day Moving Average - What's Next?Clearside Biomedical (NASDAQ:CLSD) Share Price Crosses Below 50-Day Moving Average - Here's What HappenedFebruary 4, 2025 | marketbeat.comClearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical ProgramJanuary 28, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Stock Price Passes Below 50 Day Moving Average - What's Next?Clearside Biomedical (NASDAQ:CLSD) Share Price Passes Below 50 Day Moving Average - What's Next?January 25, 2025 | marketbeat.comClearside Biomedical announces ARCATUS approved in Australia, SingaporeJanuary 23, 2025 | markets.businessinsider.comClearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and SingaporeJanuary 22, 2025 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Decline in Short InterestClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 741,700 shares, a decline of 32.6% from the December 15th total of 1,100,000 shares. Based on an average daily trading volume, of 686,000 shares, the short-interest ratio is currently 1.1 days.January 15, 2025 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of "Buy" by AnalystsShares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The averageJanuary 11, 2025 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Stock Price Crosses Below 50-Day Moving Average - Here's WhyClearside Biomedical (NASDAQ:CLSD) Share Price Crosses Below 50 Day Moving Average - What's Next?December 26, 2024 | marketbeat.comClearside announces publication of insights on drug development, regulationDecember 20, 2024 | finance.yahoo.comClearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, EyeDecember 19, 2024 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Receives Consensus Rating of "Buy" from BrokeragesShares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six brokerages that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year targDecember 17, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 11.8% in NovemberClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 1,340,000 shares, a decline of 11.8% from the November 15th total of 1,520,000 shares. Based on an average daily trading volume, of 726,200 shares, the days-to-cover ratio is currently 1.8 days.December 16, 2024 | marketbeat.comClearside Biomedical Highlights Advancements in Drug DeliveryDecember 14, 2024 | markets.businessinsider.comClearside Biomedical (NASDAQ:CLSD) Rating Increased to Hold at StockNews.comStockNews.com raised Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Thursday.December 12, 2024 | marketbeat.comClearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United StatesNovember 25, 2024 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of "Buy" by AnalystsShares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have earned a consensus recommendation of "Buy" from the six brokerages that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price target among brokersNovember 22, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CLSD FY2024 Earnings?Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) - Research analysts at HC Wainwright increased their FY2024 earnings estimates for Clearside Biomedical in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst Y. Chen now anticipates that the cNovember 18, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Raised to Hold at StockNews.comStockNews.com raised Clearside Biomedical from a "sell" rating to a "hold" rating in a research note on Saturday.November 16, 2024 | marketbeat.comClearside Biomedical's (CLSD) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Friday.November 15, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a research report on Thursday.November 14, 2024 | marketbeat.comPromising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash PositionNovember 13, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Clearside Biomedical (CLSD)November 13, 2024 | markets.businessinsider.comNeedham & Company LLC Reaffirms "Buy" Rating for Clearside Biomedical (NASDAQ:CLSD)Needham & Company LLC restated a "buy" rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Wednesday.November 13, 2024 | marketbeat.comClearside Biomedical Reports Positive Q3 2024 ResultsNovember 13, 2024 | markets.businessinsider.com Remove Ads Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address CLSD Media Mentions By Week CLSD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLSD News Sentiment▼-0.140.79▲Average Medical News Sentiment CLSD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLSD Articles This Week▼52▲CLSD Articles Average Week Remove Ads Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Atai Life Sciences News Today Terns Pharmaceuticals News Today ProKidney News Today Annexon News Today Gossamer Bio News Today COMPASS Pathways News Today Septerna News Today Candel Therapeutics News Today Design Therapeutics News Today Atea Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLSD) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLSD Stock Free CLSD Stock Alerts